LON:GNS - Genus Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 2,200 -20.00 (-0.90 %) (As of 01/17/2019 04:00 PM ET)Previous CloseGBX 2,220Today's RangeGBX 2,168 - GBX 2,22052-Week RangeGBX 1,652 - GBX 2,597Volume88,479 shsAverage Volume78,154 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartDividendInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos, which are delivered through artificial insemination to breed dairy and beef cattle with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers; and agricultural and agri-food consultancy services. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom. Receive GNS News and Ratings via Email Sign-up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:GNS Previous Symbol CUSIPN/A Webwww.genusplc.com Phone+44-1256-347100Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees2,900 Outstanding SharesN/AMarket Cap£0.00 OptionableNot Optionable Genus (LON:GNS) Frequently Asked Questions What is Genus' stock symbol? Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS." How often does Genus pay dividends? What is the dividend yield for Genus? Genus declared a dividend on Thursday, September 6th. Shareholders of record on Thursday, November 15th will be given a dividend of GBX 17.90 per share on Friday, November 30th. This represents a yield of 0.7%. The ex-dividend date of this dividend is Thursday, November 15th. This is a boost from Genus's previous dividend of $8.10. The official announcement can be viewed at this link. View Genus' Dividend History. What price target have analysts set for GNS? 4 equities research analysts have issued 1-year price targets for Genus' shares. Their forecasts range from GBX 1,800 to GBX 2,630. On average, they expect Genus' stock price to reach GBX 2,357.50 in the next year. This suggests a possible upside of 7.2% from the stock's current price. View Analyst Price Targets for Genus. What is the consensus analysts' recommendation for Genus? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genus. Has Genus been receiving favorable news coverage? Press coverage about GNS stock has been trending somewhat positive on Thursday, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genus earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. Who are some of Genus' key competitors? Some companies that are related to Genus include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB). Who are Genus' key executives? Genus' management team includes the folowing people: Mr. Karim Bitar, CEO & Exec. Director (Age 53)Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 58)Dr. Jonathan Lightner, Chief of R&D and Scientific OfficerMr. Dan Hartley, Group Gen. Counsel & Company Sec.Ms. Angelle R. Rosata, Group HR Director How do I buy shares of Genus? Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Genus' stock price today? One share of GNS stock can currently be purchased for approximately GBX 2,200. What is Genus' official website? The official website for Genus is http://www.genusplc.com/. How can I contact Genus? Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100. MarketBeat Community Rating for Genus (LON GNS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 269 (Vote Outperform)Underperform Votes: 246 (Vote Underperform)Total Votes: 515MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote "Outperform" if you believe GNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: How does the Federal Reserve determine interest rates?